The Global Footwear Market is expected to grow at a CAGR of 5.8% during the forecast period of 2023 to 2030. Growing awareness of the latest footwear trends among people is increasing the demand for footwear globally. In addition, the trend of fitness exercises such as Zumba, yoga, and gym is producing huge demand for sports shoes among individuals. The increase in the number of sports lovers, athletes, and fan followers of sports such as football, basketball, and hockey is further creating higher demand for various kinds of footwear. People are highly influenced by actors and influencers and follow their unique footwear designs which surge the demand for footwear. • To achieve noteworthy business growth and maximum return on investment (ROI), adopting the finest market research report like Footwear Market is truly helpful. • This market analysis report has been framed by taking into account several factors of the present and upcoming market scenario. • This industry document comprises of most-detailed market segmentation, systematic analysis of major market players, trends in consumer and supply chain dynamics, and insights about new geographical markets. • Statistical and numerical data covered in the top-notch Footwear Market is represented using graphs and tables which make things easier the understanding of facts and figures. • The reliable Footwear Market research report assists in determining and optimizing each stage in the lifecycle of an industrial process that includes engagement, acquisition, retention, and monetization. • The analysis and estimations carried out via this industry report help to get the details about the product launches, future products, joint ventures, marketing strategy, developments, mergers and acquisitions, and the effect of the same on sales, marketing, promotions, revenue, import, export, and CAGR 13.3% values. • Global Footwear Market report contains the most recent and efficient market insights with which businesses can ponder to augment their marketing, advertising, promotional, and sales strategies. GET SAMPLE OF THE REPORT https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-footwear-market Footwear Market Analysis and Size The global footwear market appears to be fragmented due to the presence of many well-established companies. Furthermore, this raises the level of competition in the market. As a result, players are employing various strategies such as mergers, acquisitions, and joint ventures to maintain their market leadership. Several market players, for example, are collaborating with other companies in order to expand their production capabilities and develop innovative products. Many companies in the footwear industry are increasing their R&D efforts in order to develop next-generation products. In order to expand their customer base, they are also focused on providing cost-effective and high-quality products. These initiatives are expected to generate revenue opportunities in the global footwear industry. Market Definition Footwear refers to garments worn on the feet that were originally designed to protect against environmental adversities, most notably ground textures and temperature. Footwear Market Dynamics This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below: • increasing demand for convenient and comfortable footwear Due to the high demand for convenient and comfortable footwear, and companies focusing on a few key specifications, such as creative designs, product advancements, and advanced technical manipulations, the footwear market is expected to grow. • Increased sports activities and technological advancement the rise in sports activities, emphasis on performance, and technological advancements have resulted in the footwear gaining immense popularity in sportswear, as well as the growing demand for fashionable, comfortable, and convenient footwear, as well as the growing number of working people around the world, are some of the key factors expected to drive the footwear market during the forecast period. Segmentation: Global Footwear Market The footwear market is segmented on the basis of type, shoe material, soling material, distribution channel and end user. • On the basis of type, the footwear market is segmented loafer, shoes, sandals/flip-flops, ballerinas, boots, wedges, athletic, healthcare shoes, and others. • Based on shoe material, the footwear market is segmented into plastic, rubber, leather, textile, and others. • On the basis of soling material, the footwear market is segmented into plastic, rubber, leather, and others. • On the basis of distribution channel, the footwear market is segmented into e-commerce, specialty stores, supermarkets/hypermarkets, convenience stores, and others. • On the basis of end user, the footwear market is segmented into women, men, and children. Global Footwear Market Scope The footwear market is segmented on the basis of product type, material, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications. Product Type • Athletic • Non athletic Based on product type, the footwear market is segmented into athletic, non-athletic footwear. Material • Plastic • Synthetic rubber • Plant based • Others Based on material, the footwear market is segmented into plastic, synthetic rubber, leather, plant based, others. Distribution channel • Hypermarkets • Online channels • Specialty stores • Others Based on distribution channel, the footwear market is segmented into hypermarkets, online channels, specialty stores, others. • End users • Men • Women kids Based on end-user, the footwear market is segmented into men, women, kids. Footwear Market Regional Analysis/Insights The footwear market is analysed and market size insights and trends are provided by country, product type, material, end-user and distribution channel as referenced above. The countries covered in the footwear market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. Asia-Pacific dominates the footwear market due to the presence of a large consumer usage base in developing countries such as China, India, and Indonesia, as well as the region's growing demand for athletic and non-athletic footwear usage. Competitive Landscape and Footwear Market Share Analysis The footwear market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to footwear market. Some of the major players operating in the footwear market are: • Bata Brand (India) • Honeywell International Inc. (U.S.) • Wolverine World Wide Inc. (U.S.) • Rahman Group (India) • Dunlop Protective Footwear (Portugal) • VF Corporation (U.S.) • Uvex group (Germany) • Hewat's Edinburgh (U.K.) • ELTEN GmbH (Germany) • COFRA Holding (Switzerland) • Rock Fall Ltd. (U.K.) • Oftenrich Holdings Co. Ltd. (U.S.) Get Full Access to the Report https://www.databridgemarketresearch.com/reports/global-footwear-market Table of Content: Part 01: Executive Summary Part 02: Scope of the Report Part 03: Global Footwear Market Part 04: Global Footwear Market Sizing Part 05: Global Footwear Market Segmentation by Product Part 06: Five Forces Analysis Part 07: Customer Landscape Part 08: Geographic Landscape Part 09: Decision Framework Part 10: Drivers and Challenges Part 11: Market Trends Part 12: Vendor Landscape Part 13: Vendor Analysis Get TOC Details https://www.databridgemarketresearch.com/toc/?dbmr=global-footwear-market Browse Related Reports@ https://www.databridgemarketresearch.com/reports/global-radar-sensor-market https://www.databridgemarketresearch.com/reports/global-caustic-soda-flakes-market https://www.databridgemarketresearch.com/reports/middle-east-and-africa-dry-eye-syndrome-treatment-market https://www.databridgemarketresearch.com/reports/global-smart-glasses-market https://www.databridgemarketresearch.com/reports/asia-pacific-edible-oils-market About Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email: Sopan.gedam@databridgemarketresearch.com

The Middle East and Africa dermal fillers market which was USD 205.75 million in 2022, is expected to reach up to USD 450.76 million by 2030 and is expected to undergo a CAGR of 10.3 % during the forecast period Get a sample of the report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=middle-east-and-africa-dermal-fillers-market Middle East and Africa Dermal Fillers Market Analysis and Insight • The dermal filler is a gel-like substance that are injected underneath the skin to restore lost volume, often creases and smooth lines or enhance facial contours. Dermal fillers usage has rapidly grown in recent years because of various offerings in enhancing aesthetic and rejuvenate improvements that were previously only achievable with surgeries. • These are becoming very popular for facial rejuvenation methods. Being a minimally invasive dermal filler shows instantaneous results in cosmetic volume replacement therapies. These devices provide volume to the face, and boost and enhance the quality of the skin. Various methods such as injections are used for augmentation. These fillers can give fuller, plumper lips for aesthetic purposes. There are many types of dermal fillers that can be injected in lips and around mouth that keep the volume of lips either temporally or permanently depending on the type of product used. Some market players are involved in the new and innovative products and their products are under pipeline. During the last few years, new innovative dermal fillers products have been developed for increasing the market growth of the dermal fillers market and the market players are enhancing their product portfolio. Many market players are involved in the manufacturing of dermal fillers with innovations that pave the way for market growth. Dermal Fillers Market Segmentation The dermal fillers market is segmented on the basis of product type, material type, application, drug type, end user and distribution channel. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. • By Product Type • Biodegradable Dermal Fillers • Non-Biodegradable Dermal Fillers • On the basis of product type, the dermal fillers market is segmented into biodegradable dermal fillers and non-biodegradable dermal fillers. • By Material Type • Natural Dermal Fillers • Synthetic Dermal Fillers • On the basis of material type, the market is segmented into natural dermal fillers and synthetic dermal fillers. • By Application • Face Lift • Rhinoplasty • Reconstructive Surgery • Facial Line Correction • Lip Enhancement • Sagging Skin • Cheek Depression • Skin Smoothing • Dentistry • Aesthetic Restoration • Lip Plum • Scar Treatment • Chin Augmentation • Lipoatrophy Treatment • Earlobe Rejuvenation • Others • On the basis of application, the market is segmented into face lift, rhinoplasty, reconstructive surgery, facial line correction, lip enhancement, sagging skin, cheek depression, skin smoothing, dentistry, aesthetic restoration, scar treatment, chin augmentation, lipoatrophy treatment, earlobe rejuvenation and others. • By Drug Type • Branded • Generic • On the basis of drug type, the market is segmented into branded and generic. • By End User • Dermatology Clinics • Hospitals • Ambulatory Surgical Centers • Academic Research Institutes • Others • On the basis of end user, the market is segmented into dermatology clinics, ambulatory surgical centers, hospitals, academic research institutes and others. • By Distribution Channel • Direct Tender • Drug Stores • Retail Pharmacy • Online Pharmacy • Others Dermal Fillers Market Regional Analysis/Insights The dermal fillers market is analyzed and market size insights and trends are provided by country, by product type, by material type, by application, by drug type, by end user and by distribution channel as referenced above. Competitive Landscape and Dermal Fillers Market Share Analysis The dermal fillers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus on the dermal fillers market. Some of the major players operating in the market are Allergan(A Subsidiary of Abbvie, Inc.), Prollenium Medical Technologies, Suneva Medical, Revance Therapeutics, Inc., FillMed Laboratories, Anika Therapeutics, Inc, Ipsen Pharma, BIOXIS Pharmaceuticals, Zimmer Aesthetic, Zhejiang Jingjia Medical Technology Co. Ltd., Medytox, Contura International ltd., Shanghai Reyoungel Medical Technology Company Limited, Humedix (A subsidiary of HUONS GLOBAL),Galderma Laboratories, L.P., Merz North America, Inc. (A Subsidiary of Merz Pharma),Croma-Pharma GmbH, Sinclair Pharma (A Subsidiary of Huadong Medicine Co., Ltd.),Teoxane, BioPlus Co., Ltd., Amalian, Givaudan, Mesoestetic, Sosum Global, DSM, IBSA Nordic ApS,among others. Get Full Access to the Report https://www.databridgemarketresearch.com/reports/middle-east-and-africa-dermal-fillers-market MAJOR TOC OF THE REPORT Chapter One: Introduction Chapter Two: Market Segmentation Chapter Three: Market Overview Chapter Four: Executive Summary Chapter Five: Premium Insights Chapter Six: Middle East and Africa Dermal Fillers Market Get TOC Details https://www.databridgemarketresearch.com/toc/?dbmr=middle-east-and-africa-dermal-fillers-market Top trending reports https://www.databridgemarketresearch.com/reports/global-sesame-seed-oil-market https://www.databridgemarketresearch.com/reports/global-cricket-equipment-market https://www.databridgemarketresearch.com/reports/global-marine-incinerators-market https://www.databridgemarketresearch.com/reports/global-nutritional-lipid-market https://www.databridgemarketresearch.com/reports/global-plush-blankets-market https://www.databridgemarketresearch.com/reports/global-hybrid-food-market https://www.databridgemarketresearch.com/reports/global-antioxidant-vitamin-market About Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email: Sopan.gedam@databridgemarketresearch.com

The Non-Surgical Skin Tightening Market exhibited significant growth in 2022, with a market value of USD 3.21 billion, and it is projected to reach USD 7.35 billion by 2032, boasting a compound annual growth rate (CAGR) of 7% during the forecast period. This remarkable expansion is primarily attributed to the increasing popularity of non-invasive and painless techniques, which cater to individuals seeking to enhance their appearance without resorting to surgery, either due to personal preferences or health constraints. https://www.reportsanddata.com/report-detail/non-surgical-skin-tightening-market

Antibody Drug Conjugate market Size, Share, Trends by 2035 The potential of antibody drug conjugates for the treatment of various disease indications, including cancer, is being slowly recognized in the pharmaceutical sector. Specifically, the success of these products can be attributed to their ability to effectively identify and eliminate diseased cells, along with low risk of side effects. The financial opportunity within the antibody drug conjugate market has been analyzed across the following segments:  Target Disease Indication  Acute Lymphoblastic Leukemia  Breast Cancer  B-Cell Lymphoma  Cervical Cancer  Gastric Cancer  Lung Cancer  Multiple Myeloma  Renal Cancer  Other Target Disease Indications  Therapeutic Area  Hematological Cancer  Solid Tumor  Linker  Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (Acbut)  Maleimide  Maleimidocaproyl  Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate  Tetrapeptide-Based Linker  Valine-Alanine  Valine-Citrulline  Other Linkers  Payload  DM1  DM4  Duocarmycin  Monomethyl auristatin E (MMAE)  Monomethyl auristatin F (MMAF)  Ozogamicin  SG3199  SN-38 / Irinotecan  Other Payloads  Target Antigen  BCMA (TNFRSF17 / BCM)  CD19  CD22  CD30  CD79b  CEACAM5  HER-2 (ERBB2)  Nectin 4  Tissue factor  TROP-2  Other Target Antigen  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World The Antibody Drug Conjugate Market (7th Edition), 2023-2035 report features the following companies, which we identified to be key players in this domain:  ADC Therapeutics  Astellas Pharma  AstraZeneca  Byondis  Daiichi Sankyo  Genentech  Gilead Sciences  ImmunoGen  Pfizer  RemeGen Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Landscape 5. Target Competitiveness Analysis 6. Company and Drug Profiles 7. Clinical Trial Analysis 8. Key Opinion Leaders 9. Combination Therapies 10. Partnerships and Collaborations 11. Funding and Investment Analysis 12. Patent Analysis 13. Academic Grants Analysis 14. Key Commercialization Strategies 15. Promotional Analysis 16. Success Protocol Analysis 17. Novel Conjugation and Linker Technology Platforms 18. Assessment of Non-Clinical Data First in Human Dosing 19. Cost Price Analysis 20. Case Study 1: Contract Manufacturing of Antibody-Drug Conjugates 21. Case Study 2: Companion Diagnostics for Antibody-Drug Conjugate Therapeutics 22. SWOT Analysis 23. Market Sizing and Opportunity Analysis 24. Executive Insights 25. Conclusion 26. Appendix 1: Tabulated Data 27. Appendix 2: List of Companies and Organizations To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market/270.html Learn from experts: do you know about these emerging industry trends? Digital Therapies: The “Digital Pills” of current generation Medical Device Coatings and Modification Technologies Learn from our recently published whitepaper: - Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Learn more about Roots Analysis consulting services: Roots Analysis Consulting - the preferred research partner for global firms Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #ADCMarket #antibodydrugconjugate #antibodydrugconjugatemarket #MarketResearch #MarketInsights

Intracellular Drug Delivery market Growth Analysis and Forecast by 2035 The growing demand for novel drugs that can acts as potential treatments for previously untreatable intracellular targets has resulted in an adjacent and urgent need for efficient delivery systems that facilitate intracellular transport of therapeutics across the cytosol The financial opportunity within non-viral drug delivery systems market has been analyzed across the following segments:  Type of Molecule  Small Molecule  Biologic  Type of Biologic  Antibodies  DNA  RNA  Proteins / Peptides  Type of Intracellular Drug Delivery Technologies  Cell Penetrating Peptides  Extracellular Vesicles  Oligonucleotides  Nanoparticles  Polymers  Target Therapeutic Area  Infectious Diseases  Oncological Disorders  Genetic Disorders  Neurological Disorders  Hepatic Disorders  Cardiovascular Disorders  Other Disorders  Type Of Payment Model  Upfront Payments  Milestone Payments  Key Geographical Regions  North America  Europe  Asia  Latin America  Middle East and North Africa (MENA)  Rest of the world The Non-Viral Drug Delivery Systems Market: Focus on Intracellular Technologies and Biologics (2nd Edition), 2022-2035, report features the following companies, which we identified to be key players in this domain:  Alnylam Pharmaceuticals  AstraZeneca  Biond Biologics  Code Biotherapeutics  Eli Lilly  Merck  Novartis  Roche Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Landscape 5. Key Insights 6. Company Competitiveness Analysis 7. Company Profiles 8. Patent Analysis 9. Partnerships and Collaborations 10. Opportunity Assessment Framework 11. Market Forecast 12. Conclusion 13. Executive insights 14. Appendix I: Tabulated data 15. Appendix II: List of Companies and Organizations To view more details on this report, click on the link https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html News article AI-based Digital Pathology Market Learn from experts: do you know about these emerging industry trends? Antiviral Drugs Development: Are we Prepared for the Next Viral Pandemic? Exploring How Artificial Intelligence Is Transforming Digital Pathology About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Learn more about Roots Analysis consulting services: Roots Analysis Consulting - the preferred research partner for global firms Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #nonviraldrugdeliverysystemmarket #Intracellularbiologics #intracellulardelivery #MarketResearch #MarketInsights

Bacteriophage therapy market Professional Survey Report by 2035 With the ever-increasing burden of antimicrobial resistance, the focus of the research community has shifted towards the development of alternatives for the treatment of infectious diseases. One of such alternatives is bacteriophage therapeutics. The innovators suggests that the success of these therapies lies in the effectiveness of phages to target the desired bacterial strains. The financial opportunity within the bacteriophage therapeutics market has been analyzed across the following segments:  Type of Therapeutic Area  Infectious Diseases  Oncological Disorders  Other Disorders  Distribution by Route of Administration  Oral Route  Rectal Route  Intravesical Route  Topical Route  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa The “Bacteriophage Therapy Market, 2022-2035” report features the following companies, which we identified to be key players in this domain:  Adaptive Phage Therapeutics  ContaFect  Eliava BioPreparations  Micreos  NPO Microgen  Phagelux  Pherecydes Pharma Table of Content 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. BACTERIO-PHAGE THERAPY: MARKET LANDSCAPE 5. BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE 6. COMPANY AND DRUG PROFILES 7. CLINICAL TRIAL ANALYSIS 8. PATENT ANALYSIS 9. PUBLICATION BENCHMARKING ANALYSIS 10. ACADEMIC GRANTS ANALYSIS 11. FUNDING AND INVESTMENT ANALYSIS 12. PARTNERSHIPS AND COLLABORATIONS 13. START-UP HEALTH INDEXING 14. MARKET FORECAST AND OPPORTUNITY ANALYSIS 15. CONCLUSION 16. EXECUTIVE INSIGHTS 17. APPENDIX I: TABULATED DATA 18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html You may also be interested in the following titles: Cannabis Testing Market Key Trends in Non-Viral Transfection Market CAR-T Cell Therapy Market Roots Analysis Consulting - the preferred research partner for global firms About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #bacteriophagetherapy #bacteriophagetherapeutics #phagetherapy #MarketResearch #MarketInsights

Quantum Computing market 2022 – Industry Growth by 2035 Roots Analysis has announced the addition of “Quantum Computing in Drug Discovery Services Market, 2023-2035” report to its list of offerings. Key Market Insights  Presently, over 45 players around the globe claim to offer quantum computing services across different steps of drug discovery  Leveraging their expertise, 86% stakeholders offer such services across target discovery / identification, primarily focusing on oncological disorders  In pursuit of gaining a competitive edge, manufacturers claim to be steadily expanding their existing capabilities in order to enhance their service portfolio related to quantum computing  Grants worth over USD 70 million have been awarded to various organizations that have actively undertaken R&D efforts to evaluate the potential of quantum computing in drug discovery  A considerable increase in the partnership activity has been witnessed in the past few years; close to 50% of the collaborations were inked by firms based in the same region  More than 30 players, worldwide, claim to offer hardware-as-a-service for quantum computing in drug discovery, and have developed the required expertise in different types of computational approaches  Majority of the quantum computing hardware providers, headquartered in North America, were established before the year 2000; in fact, ~50% of the overall market landscape is catered to by large companies.  The rise in the adoption of quantum computing in the biopharmaceutical industry is anticipated to create profitable business opportunities for both software and hardware providers  Based on the pioneer-migrator-settler map, we have classified the software providers into different categories; a selection of pioneers is expected to provide valuable offerings to lead the market in the longer term  We expect the market to grow at an annualized rate of 14% in the coming decade; the opportunity is likely to be well distributed across types of drug discovery services, therapeutic areas and key geographical regions Table of Contents 1. PREFACE 1.1. Introduction 1.2. Key Market Insights 1.3. Scope of the Report 1.4. Research Methodology 1.5. Frequently Asked Questions 1.6. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Overview of Quantum Computing in Drug Discovery 3.2. Drug Discovery and Development Timeline 3.3. Historical Evolution of Computational Drug Discovery Approaches 3.4. Classification of Quantum Computing Approaches 3.5. Applications of Quantum Computing in Drug Discovery Process 3.6. Advantages of Quantum Computing in Drug Discovery 3.7. Challenges Associated with Quantum Computing in Drug Discovery 3.8. Future Perspectives 4. MARKET LANDSCAPE: SOFTWARE PROVIDERS 4.1. Quantum Computing Software Providers: Overall Market Landscape 4.1.1. Analysis by Year of Establishment 4.1.2. Analysis by Company Size 4.1.3. Analysis by Location of Headquarters 4.1.4. Analysis by Business Capabilities 4.1.5. Analysis by Platform Capabilities 4.1.6. Analysis by Type of Drug Discovery Service(s) Offered 4.1.7. Analysis by Type of Molecule(s) Supported 4.1.8. Analysis by Compatible Computational Approaches 4.1.9. Analysis by End User(s) 4.1.10. Analysis by Therapeutic Area(s) 5. COMPANY COMPETITIVENESS ANALYSIS 5.1. Methodology and Key Parameters 5.2 Scoring Criteria 5.3. Company Competitiveness Analysis: Players based in North America (Peer Group I) 5.4. Company Competitiveness Analysis: Players based in Europe (Peer Group II) 5.5. Company Competitiveness Analysis: Players based in Asia-Pacific and Rest of the World (Peer Group III) 6. COMPANY PROFILES: SOFTWARE PROVIDERS 6.1. Accenture 6.1.1. Company Overview 6.1.2. Financial Information 6.1.3. Service Portfolio 6.1.4. Recent Developments and Future Outlook 6.2. Atos 6.3. Fujitsu 6.4. Huawei 6.5. Microsoft 6.6. Xanadu 6.7. XtalPi 7. MARKET LANDSCAPE: HARDWARE PROVIDERS 7.1. Quantum Computing Hardware Providers: Overall Market Landscape 7.1.1. Analysis by Year of Establishment 7.1.2. Analysis by Company Size 7.1.3. Analysis by Region of Headquarters 7.1.4. Analysis by Location of Headquarters 7.1.5. Analysis by Type of Offering(s) 7.1.6. Analysis by Data Storage on Cloud 7.1.7. Analysis by Compatible Computational Approaches 7.1.8. Analysis by Type of Offering(s) and Compatible Computational Approaches 8. COMPANY PROFILES: HARDWARE PROVIDERS 8.1. Amazon Web Services 8.1.1. Company Overview 8.1.2. Financial Information 8.1.3. Service Portfolio 8.1.4. Recent Developments and Future Outlook 8.2. IBM 8.3. Microsoft 9. ACADEMIC GRANTS ANALYSIS 9.1. Analysis Methodology 9.2. Key Parameters 9.3. Analysis by Year of Grant 9.4. Analysis by Amount Awarded 9.5. Analysis by Support Period 9.6. Analysis by Study Section 9.7. Word Cloud Analysis: Emerging Focus Areas 9.8. Analysis by Administering Institute Center 9.9. Analysis by Type of Grant 9.10. Analysis by Activity Code 9.11. Analysis by Purpose of Grant 9.12. Analysis by Administering Institute Center and Support Period 9.13. Prominent Program Officers: Analysis by Number of Grants 9.14. Analysis by Location of Recipient Organizations 9.15. Analysis by Type of Organization 9.16. Popular Recipient Organizations: Analysis by Number of Grants 9.17. Popular Recipient Organizations: Analysis by Amount Awarded 10. PARTNERSHIPS AND COLLABORATIONS 10.1. Partnership Models 10.2. Quantum Computing in Drug Discovery, Drug Manufacturing and Other Services: Partnerships and Collaborations 10.3. Analysis by Year of Partnership 10.4. Analysis by Type of Partnership 10.5. Analysis by Year and Type of Partnership 10.6. Most Active Players: Analysis by Number of Partnerships 10.7. Word Cloud Analysis: Key Focus Areas 10.8. Analysis by Type of Continent 10.9. Analysis by Company Size and Type of Partnership 10.10. Local and Intercontinental Agreements 10.11. Intercontinental and Intracontinental Agreements 11. USE CASE STUDY 11.1. Overview of Quantum Computing 11.2. Applications of Quantum Computing Across Various Industries 11.3. Upcoming Trends in Quantum Computing 11.4. Future Perspectives 12. PORTER’S FIVE FORCES ANALYSIS 12.1. Methodology and Assumptions 12.2. Key Parameters 12.2.1. Threats of New Entrants 12.2.2. Bargaining Power of Buyers 12.2.3. Bargaining Power of Suppliers 12.2.4. Threats of Substitute Products 12.2.5. Rivalry among Existing Competitors 13. BLUE OCEAN STRATEGY: A STRATEGIC GUIDE FOR START-UPS TO ENTER INTO HIGHLY COMPETITIVE MARKET 13.1. Overview of Blue Ocean Strategy 13.1.1 Red Oceans 13.1.2 Blue Oceans 13.1.3 Comparison of Red Ocean Strategy and Blue Ocean Strategy 13.1.4. Quantum Computing in Drug Discovery Services Market: Blue Ocean Strategy and Shift Tools 13.1.4.1. Value Innovation 13.1.4.2. Strategy Canvas 13.1.4.3. Four Action Framework 13.1.4.4. Eliminate-Raise-Reduce-Create (ERRC) Grid 13.1.4.5. Six Path Framework 13.1.4.6. Pioneer-Migrator-Settler (PMS) Map 13.1.4.7. Three Tiers of Non-customers 13.1.4.8. Sequence of Blue Ocean Strategy 13.1.4.9. Buyer Utility Map 13.1.4.10. The Price Corridor of the Mass 13.1.4.11. Four Hurdles to Strategy Execution 13.1.4.12. Tipping Point Leadership 13.1.4.13. Fair Process 14. MARKET SIZING AND OPPORTUNITY ANALYSIS 14.1. Forecast Methodology and Key Assumptions 14.2. Quantum Computing in Drug Discovery Services Market, 2023-2035 14.2.1. Quantum Computing in Drug Discovery Services Market, 2023-2035: Analysis by Type of Drug Discovery Service Offered 14.2.1.1. Quantum Computing in Drug Discovery Services Market for Target Identification / Validation, 2023-2035 14.2.1.2. Quantum Computing in Drug Discovery Services Market for Hit Generation / Lead Identification, 2023-2035 14.2.1.3. Quantum Computing in Drug Discovery Services Market for Target Lead Optimization, 2023-2035 14.2.2. Quantum Computing in Drug Discovery Services Market, 2023-2035: Analysis by Therapeutic Area 14.2.2.1. Quantum Computing in Drug Discovery Services Market for Cardiovascular Disorders, 2023-2035 14.2.2.2. Quantum Computing in Drug Discovery Services Market for CNS Disorders, 2023-2035 14.2.2.3. Quantum Computing in Drug Discovery Services Market for Dermatological Disorders, 2023-2035 14.2.2.4. Quantum Computing in Drug Discovery Services Market for Endocrine Disorders, 2023-2035 14.2.2.5. Quantum Computing in Drug Discovery Services Market for Gastrointestinal Disorders, 2023-2035 14.2.2.6. Quantum Computing in Drug Discovery Services Market for Immunological Disorders, 2023-2035 14.2.2.7. Quantum Computing in Drug Discovery Services Market for Infectious Diseases, 2023-2035 14.2.2.8. Quantum Computing in Drug Discovery Services Market for Musculoskeletal Disorders, 2023-2035 14.2.2.9. Quantum Computing in Drug Discovery Services Market for Oncological Disorders, 2023-2035 14.2.2.10. Quantum Computing in Drug Discovery Services Market for Respiratory Disorders, 2023-2035 14.2.2.11. Quantum Computing in Drug Discovery Services Market for Others, 2023-2035 14.2.3. Quantum Computing in Drug Discovery Services Market, 2023-2035: Analysis by Key Geographical Regions 14.2.3.1. Quantum Computing in Drug Discovery Services Market in North America, 2023-2035 14.2.3.1.1. Quantum Computing in Drug Discovery Services Market in the US, 2023-2035 14.2.3.1.2. Quantum Computing in Drug Discovery Services Market in Canada, 2023-2035 14.2.3.2. Quantum Computing in Drug Discovery Services Market for Europe, 2023-2035 14.2.3.2.1. Quantum Computing in Drug Discovery Services Market in the UK, 2023-2035 14.2.3.2.2. Quantum Computing in Drug Discovery Services Market in France, 2023-2035 14.2.3.1.3. Quantum Computing in Drug Discovery Services Market in Germany, 2023-2035 14.2.3.1.4. Quantum Computing in Drug Discovery Services Market in Rest of the Europe, 2023-2035 14.2.3.3. Quantum Computing in Drug Discovery Services Market in Asia-Pacific, 2023-2035 14.2.3.3.1. Quantum Computing in Drug Discovery Services Market in China, 2023-2035 14.2.3.3.2. Quantum Computing in Drug Discovery Services Market in Japan, 2023-2035 14.2.3.3.3. Quantum Computing in Drug Discovery Services Market in Rest of Asia-Pacific, 2023-2035 14.2.3.4. Quantum Computing in Drug Discovery Services Market in Latin America, 2023-2035 14.2.3.5. Quantum Computing in Drug Discovery Services Market in Middle East and North Africa, 2023-2035 15. EXECUTIVE INSIGHTS 16. APPENDIX 1: TABULATED DATA 17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To view more details on this report, click on the link https://www.rootsanalysis.com/reports/quantum-computing-in-drug-discovery.html You may also be interested in the following titles: Lab Automation Market Cannabis Testing Market About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #QuantumComputingMarket #QuantumComputingMarketSize #quantumcomputinginhealthcare #quantumcomputingindrugdiscovery #quantumcomputing

non-viral drug delivery system market 2022 – Industry Growth by 2035 Roots Analysis has announced the addition of “Non-Viral Drug Delivery Systems Market: Focus on Intracellular Technologies and Biologics (2nd Edition), 2022-2035” report to its list of offerings. Key Market Insights  Presently, over 90 non-viral drug delivery systems developers are engaged in the healthcare market, located across the globe  Currently, more than 95 non-viral drug delivery systems are offered by several players in the healthcare domain  The partnership activity for non-viral drug delivery systems in the healthcare domain has grown at a CAGR of over 40%, in the past three years, 2018-2021  The projected future opportunity for companies engaged in this field is expected to be well distributed across type of molecule, type of biologic delivered, type of technology, target therapeutic area, type of payment model and key geographical regions. Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Market Segmentations 1.4. Key Questions Answered 1.5. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Need for Targeted Drug Delivery 3.3. Advanced Approaches for Delivery of Drug Payloads 3.3.1. Nanoparticle Delivery Systems 3.3.1.1. Liposomes 3.3.1.2. Nanoparticles / Microparticles 3.3.1.3. PEGylation 3.3.1.4. Cell Penetrating Peptides (CPPs) 3.3.2. Other Drug Delivery Technologies 3.4. Future Perspectives 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Intracellular Drug Delivery: List of Technologies 4.2.1. Analysis by Type of Molecule Delivered 4.2.2. Analysis by Type of Biologic Delivered 4.2.3. Analysis by Type of Interaction 4.2.4. Analysis by Therapeutic Portfolio 4.3. Intracellular Drug Delivery: List of Technology Developers 4.3.1. Analysis by Year of Establishment 4.3.2. Analysis by Company Size 4.3.3. Analysis by Type of Company 4.3.4. Analysis by Location of Headquarters (By Region) 5. KEY INSIGHTS 5.1. Chapter Overview 5.2. Analysis by Type of Technology 5.3. Analysis by Company Size and Type of Molecule Delivered 5.4. Analysis by Location of Headquarters (Region-wise) and Type of Service Provider 5.5. Analysis by Company Size and Location of Headquarters 6. COMPANY COMPETITIVENESS ANALYSIS 6.1. Chapter Overview 6.2. Assumptions / Key Parameters 6.3. Methodology 6.4. Company Competitiveness Analysis: Benchmarking of Portfolio Strength 6.5. Company Competitiveness Analysis: Benchmarking of Partnership Strength 6.5.1. Company Competitiveness Analysis: Very Small Companies 6.5.2. Company Competitiveness Analysis: Small Companies 6.5.3. Company Competitiveness Analysis: Mid-Sized Companies 6.5.4. Company Competitiveness Analysis: Large and Very Large Companies 7. COMPANY PROFILES 7.1. Arcturus Therapeutics 7.2. Bio-Path 7.3. CureVac 7.4. Entos Pharmaceuticals 7.5. eTheRNA immunotherapies 7.6. Matinas BioPharma 7.7. MDimune 7.8. PCI Biotech 8. PATENT ANALYSIS 8.1. Chapter Overview 8.2. Scope and Methodology 8.3. Intracellular Drug Delivery Technologies: Patent Analysis 8.3.1. Analysis by Type of Patent 8.3.2. Analysis by Publication Year 8.3.3. Analysis by Application Year 8.3.4. Analysis by Cumulative Number of Granted Patents 8.3.5. Analysis by Cumulative Number of Patent Applications 8.3.6. Analysis by Issuing Authority 8.3.7. Analysis by Type of Player 8.3.8. Leading Players: Analysis by Number of Patents 8.3.9. Leading Inventors: Analysis by Number of Patents 8.3.10. Analysis by Top Sections 8.3.11. Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis 8.4. Intracellular Drug Delivery Technologies: Patent Valuation Analysis 9. PARTNERSHIPS AND COLLABORATIONS 9.1. Chapter Overview 9.2. Partnership Models 9.3. Intracellular Drug Delivery Technologies: List of Partnerships and Collaborations 9.3.1. Cumulative Analysis of Partnerships by Year, 2015-2022 9.3.2. Analysis by Type of Partnership 9.3.3. Analysis by Year and Type of Partnership, 2015-2022 9.3.4. Analysis by Purpose of Partnership 9.3.5. Analysis by Type of Molecule Delivered 9.3.6. Analysis by Type of Biologic Delivered 9.3.7. Analysis by Target Therapeutic Area 9.3.8 Analysis by Year of Partnership and Type of Payment Model Employed, 2015-2022 9.3.9. Analysis by Year of Partnership and Type of Company, 2015-2022 9.3.10. Analysis by Purpose of Partnership and Type of Company 9.3.11. Most Active Players: Analysis by Number of Partnerships 9.3.12. Most Popular Technologies: Analysis by Number of Partnerships 9.3.13. Analysis by Region 9.3.14. Local and International Agreements 9.3.15. Intracontinental and Intercontinental Agreements 10. OPPORTUNITY ASSESSMENT FRAMEWORK: KALBACH INNOVATION MODEL, COMPETITVE ASSESSMENT FRAMEWORK AND BCG MATRIX 10.1. Chapter Overview 10.2. Kalbach Innovation Model 10.2.1. Key Assumptions and Methodology 10.2.2. Analysis by Trends in Research Activity 10.2.3. Analysis by Trends in Investment Activity 10.2.4. Analysis by Trends in Partnership Activity 10.2.5. Analysis by Number of Technologies 10.2.6. Analysis by Trends in Deal Amount 10.2.7. Analysis by Number of Google Hits 10.2.8. Qualitative and Quantitative Assessment based on Secondary and Primary Research 10.2.9. Kalbach Innovation Model: Output Analysis 10.3. Competitive Assessment Framework 10.3.1. Key Assumptions and Methodology 10.3.2. Competitive Assessment Framework: Output Analysis 10.4. BCG Matrix 10.4.1. Key Assumptions and Methodology 10.4.2. BCG Matrix: Output Analysis 11. MARKET FORECAST AND OPPORTUNITY ANALYSIS 11.1. Chapter Overview 11.2. Key Assumptions 11.3. Forecast Methodology 11.4. Global Non-Viral Intracellular Drug Delivery Technologies Market, 2022-2035 11.5. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed, 2022 and 2035 11.5.1 Non-Viral Intracellular Drug Delivery Technologies Market for Milestone Payments, 2022-2035 11.5.2 Non-Viral Intracellular Drug Delivery Technologies Market for Upfront Payments, 2022-2035 11.6. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered, 2022 and 2035 11.6.1 Non-Viral Intracellular Drug Delivery Technologies Market for Biologics, 2022-2035 11.6.2 Non-Viral Intracellular Drug Delivery Technologies Market for Small Molecules, 2022-2035 11.7. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Biologic Delivered, 2022 and 2035 11.7.1 Non-Viral Intracellular Drug Delivery Technologies Market for RNA, 2022-2035 11.7.2 Non-Viral Intracellular Drug Delivery Technologies Market for DNA, 2022-2035 11.7.3 Non-Viral Intracellular Drug Delivery Technologies Market for Proteins / Peptides, 2022-2035 11.7.4 Non-Viral Intracellular Drug Delivery Technologies Market for Antibodies, 2022-2035 11.8. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Technology, 2022 and 2035 11.8.1. Non-Viral Intracellular Drug Delivery Technologies Market for Nanoparticles, 2022-2035 11.8.2 Non-Viral Intracellular Drug Delivery Technologies Market for Extracellular Vesicles, 2022-2035 11.8.3 Non-Viral Intracellular Drug Delivery Technologies Market for Polymers, 2022-2035 11.8.4 Non-Viral Intracellular Drug Delivery Technologies Market for Oligonucleotides, 2022-2035 11.8.5 Non-Viral Intracellular Drug Delivery Technologies Market for Cell Penetrating Peptides, 2022-2035 11.9. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Target Therapeutic Areas, 2022 and 2035 11.9.1 Non-Viral Intracellular Drug Delivery Technologies Market for Infectious Diseases, 2022-2035 11.9.2 Non-Viral Intracellular Drug Delivery Technologies Market for Oncological Disorders, 2022-2035 11.9.3 Non-Viral Intracellular Drug Delivery Technologies Market for Genetic Disorders, 2022-2035 11.9.4 Non-Viral Intracellular Drug Delivery Technologies Market for Cardiovascular Disorders 2022-2035 11.9.5 Non-Viral Intracellular Drug Delivery Technologies Market for Hepatic Disorders, 2022-2035 11.9.6 Non-Viral Intracellular Drug Delivery Technologies Market for Neurological Disorders, 2022-2035 11.9.7 Non-Viral Intracellular Drug Delivery Technologies Market for Other Diseases, 2022-2035 11.10. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Geography, 2022 and 2035 11.10.1. Non-Viral Intracellular Drug Delivery Technologies Market in North America, 2022-2035 11.10.2. Non-Viral Intracellular Drug Delivery Technologies Market in Europe, 2022-2035 11.10.3. Non-Viral Intracellular Drug Delivery Technologies Market in Asia, 2022-2035 11.10.4. Non-Viral Intracellular Drug Delivery Technologies Market in Rest of the World, 2022- 2035 11.10.5. Non-Viral Intracellular Drug Delivery Technologies Market in Middle East and North Africa, 2022-2035 11.10.6. Non-Viral Intracellular Drug Delivery Technologies Market in Latin America, 2022-2035 12. CONCLUDING REMARKS 13. EXECUTIVE INSIGHTS 13.1. Chapter Overview 13.2. Biond Biologics 13.2.1. Interview Transcript: Tehila BenMoshe, Chief Executive Officer and Itay Friedman, Vice President Clinical Development 13.3. Carmine Therapeutics 13.3.1. Interview Transcript: Don Haut, Chief Executive Officer 13.4. Eyevensys 13.4.1. Interview Transcript: Thierry Bordet, Chief Scientific Officer 13.5. Generation Bio 13.5.1. Interview Transcript: Maren Killackey, Senior Director, Investor Relations and Communications 13.6. PCI Biotech 13.6.1. Interview Transcript: Anders Høgset, Research Director / Chief Scientific Officer 13.7. SRI International 13.7.1. Interview Transcript: Melissa Wagner, Strategic Business Executive, Biosciences Division 14. APPENDIX 1: TABULATED DATA 15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To view more details on this report, click on the link https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html You may also be interested in the following titles: Global Antibiotics Market Pharmaceutical Polymers / Medical Polymers Market You may also like to learn what our experts are sharing in Roots educational series: Advancements in Automation of Processes: Key Value Driver for Escalated Interest in Cell Therapies Manufacturing Domain CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #nonviraldrugdeliverysystemmarket #nonviraldrugdeliverysystemmarketSize #genedeliverysystems #intracellulardelivery #intracellulardrugdelivery

Exosome Therapeutics market Growth Analysis and Forecast by 2035 Roots Analysis has done a detailed study on Exosome Therapeutics Market, 2022-2040, covering key aspects of the industry and identifying future growth opportunities Key Market Insights  Close to 60 players, worldwide, have taken initiatives to develop exosome therapeutics; the market is characterized by the presence of start-ups and small companies  The current pipeline features more than 120 exosome therapeutics that are being evaluated across different phases of development; most of these are designed for intravenous administration  3,000+ patients have been recruited / enrolled in clinical trials evaluating exosome related therapies and biomarkers across different geographies  More than 530 grants have been awarded for the ongoing R&D efforts for exosome therapeutics; University of California has been awarded the maximum grant amount of USD 21 million  A variety of investors, having realized the benefits and future opportunities in this field, have invested more than USD 570 million across more than 30 instances, since 2017  The rising interest of stakeholders in exosome therapeutics is also reflected by the increasing number of partnerships established by various industry and non-industry players  Stakeholders have participated in various global events to discuss the research outcomes, and affiliated challenges as well as opportunities existing in this domain  At present, more than 30 start-ups are driving innovation in this domain; a variety of R&D initiatives have been undertaken by these players over the last few years for the development of exosome therapeutics  Lack of efficacy, COVID-19 pandemic, limited patient enrollment, and scarce funding are among the key reasons that have led to the discontinuation of studies sponsored by various industry and non-industry players  With the rising demand for therapeutic advances in drug safety, the market of exosome therapeutics is expected to grow at an annualized rate of 41% between 2029-2040  The projected market opportunity is likely to be well distributed across different routes of administration, types of formulations and key geographical regions Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Market Segmentation 1.3. Research Methodology 1.4. Key Questions Answered 1.5. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Overview of Exosomes 3.1.1. Types of Extracellular Vesicles 3.1.1. Potential Sources of Exosomes 3.2. Exosome Biogenesis 3.2.1. Exosome Formation and Development Process 3.2.2. Secretion of Exosomes 3.3. Applications of Exosomes 3.4. Mechanism of Exosome Therapy 3.4.1. Exosome Drug Therapy 3.4.2. Exosome RNAi Therapy 3.4.3. Exosome Immunotherapy 3.5. Advantages of Exosome Therapies 3.6. Risks and Future Perspectives Associated with Exosome Therapeutics 4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE 4.1. Analysis Methodology and Key Parameters 4.2. Exosome Therapeutics Market Landscape 4.2.1. Analysis by Phase of Development 4.2.2. Analysis by Technology Platform 4.2.3. Analysis by Type of Payload 4.2.4. Analysis by Derived Source 4.2.5. Analysis by Target Disease Indication(s) 4.2.6. Analysis by Therapeutic Area 4.2.7. Analysis by Phase of Development and Therapeutic Area 4.2.8. Analysis by Therapeutic Area and Route of Administration 4.2.9. Analysis by Route of Administration 4.2.10 Analysis by Area of Application 4.2.11. Analysis by Type of Therapy 4.2.12. Analysis by Dosing Frequency 4.2.13. Analysis by Type of Therapy (By Method of Composition) 4.2.14. Analysis by Line of Treatment 4.3. Exosome Therapeutics Developers 4.3.1. Analysis by Year of Establishment 4.3.2. Analysis by Company Size 4.3.3. Analysis by Location of Headquarters 4.3.4. Most Active Players: Analysis by Number of Therapeutics 5. EXOSOME THERAPEUTICS DEVELOPERS: COMPANY PROFILES 5.1. Coya Therapeutics 5.1.1. Company Overview 5.1.2. Product Portfolio 5.1.3. Recent Developments and Future Outlook 5.2. Codiak BioSciences 5.3.1. Company Overview 5.3.2. Product Portfolio 5.3.3. Clinical Trial Information 5.3.4. Recent Developments and Future Outlook 5.4. Evox Therapeutics 5.4.1. Company Overview 5.4.2. Product Portfolio 5.4.3. Recent Developments and Future Outlook 5.5. Curexsys 5.5.1. Company Overview 5.5.2. Product Portfolio 5.5.3. Recent Developments and Future Outlook 5.6. EV Therapeutics 5.6.1. Company Overview 5.6.2. Product Portfolio 5.6.3. Recent Developments and Future Outlook 5.7. SHIFTBIO 5.7.1. Company Overview 5.7.2. Product Portfolio 5.7.3. Recent Developments and Future Outlook 6. EXOSOME THERAPEUTICS: DRUG PROFILES 6.1. AEGLE Therapeutics 6.1.1. Company Overview 6.1.2. AGLE-102: Product Portfolio 6.1.2.1. AGLE-102: Clinical Trial Information 6.1.3. Recent Developments and Future Outlook 6.2. AVEM Healthcare 6.2.1. Company Overview 6.2.2. Ardoxso: Product Portfolio 6.2.2.1. Ardoxso: Clinical Trial Information 6.2.3. Recent Developments and Future Outlook 6.3. Cellular Biomedicine Group 6.3.1. Company Overview 6.3.2. Financial Information 6.3.3. haMPC-Exos: Product Portfolio 6.3.3.1. haMPC-Exos: Clinical Trial Information 6.3.4. hMSC-Exos: Product Portfolio 6.3.4.1. hMSC-Exos: Clinical Trial Information 6.3.5. Undisclosed Drug 1: Product Portfolio 6.3.5.1. Undisclosed Drug 1: Clinical Trial Information 6.3.6. Recent Developments and Future Outlook 6.4. OBCTCD24 6.4.1. Company Overview 6.4.2. CovenD24: Product Portfolio 6.4.2.1. CovenD24: Clinical Trial Information 6.4.3. Recent Developments and Future Outlook 6.5. ReNeuron 6.5.1. Company Overview 6.5.2. Financial Information 6.5.3. Undisclosed Drug 1: Product Portfolio 6.5.3.1. Undisclosed Drug 1: Clinical Trial Information 6.5.4. Recent Developments and Future Outlook 6.6. Stem Cell Medicine 6.6.1. Company Overview 6.6.2. Undisclosed Drug 1: Product Portfolio 6.6.3. Recent Developments and Future Outlook 7. CLINICAL TRIAL ANALYSIS 7.1. Analysis Methodology and Key Parameters 7.2. Exosome Therapeutics: List of Clinical Trials 7.2.1. Analysis by Trial Status 7.2.2. Analysis by Trial Registration Year 7.2.3. Analysis by Sponsor / Collaborator 7.2.4. Analysis by Trial Registration Year and Type of Study 7.2.5. Analysis by Trial Registration Year and Trial Status 7.2.6. Analysis by Annual Number of Patients Enrolled 7.2.7. Analysis by Study Design 7.2.8. Analysis by Age Category 7.2.9. Analysis by Phase of Development and Trial Status 7.2.10. Analysis by Phase of Development and Patients Enrolled 7.2.11. Most Active Industry Players: Analysis by Number of Registered Trials 7.2.12. Most Active Non-Industry Players: Analysis by Number of Registered Trials 7.2.13. Analysis by Trial Location 7.2.14. Analysis by Trial Status and Geography 7.2.15. Analysis by Trial Status, Patients Enrolled and Geography 8. ACADEMIC GRANT ANALYSIS 8.1. Analysis Methodology and Key Parameters 8.2. Exosome Therapeutics: List of Academic Grants 8.3. Analysis by Year of Grants Awarded 8.4. Analysis by Amount Awarded per Year 8.5. Analysis by Type of Funding Institute Center 8.6. Analysis by Support Period 8.7. Analysis by Purpose of Grant 8.8. Word Cloud Analysis: Emerging Focus Area 8.9. Analysis by Grant Activity Code 8.10. Analysis by Location of Recipient Organizations 8.11. Popular Recipient Organizations: Analysis by Number of Grants 8.12. Popular Recipient Organizations: Analysis by Amount Awarded 8.13. Analysis by Type of Recipient Organization 8.14. Analysis by Study Section 8.15. Analysis by Type of Grant Application 8.16. Analysis by Funding Institute Center and Support Year 9. GLOBAL EVENT ANALYSIS 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. List of Global Events Related to Exosomes 9.3.1. Analysis by Year of Event 9.3.2. Analysis by Event Platform 9.3.3. Analysis by Type of Event 9.3.4. Analysis by Region 9.3.5. Most Active Organizers: Analysis by Number of Events 9.3.6. Most Active Speakers: Analysis by Number of Events 9.3.7. Most Active Industry Participants: Analysis by Number of Events 9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events 9.3.9. Analysis by Designation of Participant 9.3.10. Analysis by Affiliated Department of Participant 9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area 10. PARTNERSHIPS AND COLLABORATIONS 10.1. Chapter Overview 10.2. Partnership Models 10.3. Exosome Therapeutics: List of Partnerships and Collaborations 10.3.1. Analysis by Year of Partnership 10.3.2. Analysis by Type of Partnership 10.3.3. Analysis by Year and Type of Partnership 10.3.4. Analysis by Company and Type of Partnership 10.3.5. Analysis by Type of Technology Platform 10.3.6. Analysis by Type of Partner 10.3.7. Most Active Players: Analysis by Number of Partnerships 10.3.8. Word Cloud Analysis: Emerging Focus Areas 10.3.9. Analysis by Target Disease Indication(s) 10.3.10.Analysis by Therapeutic Area 10.3.11.Analysis by Therapeutic Area and Type of Partnership 10.3.12. Regional Distribution of Partnerships 10.3.13. Distribution by Geography 11. FUNDING AND INVESTMENT ANALYSIS 11.1. Analysis Methodology and Key Parameters 11.2. Type of Funding 11.3. Exosome Therapeutics: List of Funding Instances 11.4. Analysis by Year of Funding 11.5. Analysis by Amount Invested 11.6. Analysis by Type of Funding 11.7. Analysis by Type of Funding and Amount Invested 11.8. Analysis by Purpose of Funding 11.9. Analysis by Target Disease Indication(s) 11.10. Analysis by Therapeutic Area 11.11. Most Active Players: Analysis by Number of Funding Instances 11.12. Most Active Players: Analysis by Amount Raised 11.13. Active Investors: Analysis by Number of Funding Instances 11.14. Distribution by Geography 11.15. Summary of Funding Activity 12. START-UP HEALTH INDEXING 12.1. Analysis Methodology and Key Parameters 12.2. Analysis by Pipeline Strength 12.3. Analysis by Pipeline Maturity 12.4. Analysis by Indication Diversity 12.5. Analysis by Number of Partnerships 12.6. Analysis by Financial Support 12.7. Start-up Health Indexing: Roots Analysis Perspective 12.8. Most Active Start-ups 13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS 13.1. Chapter Overview 13.2. Exosome Development and Manufacturing Service Providers Landscape 13.2.1. Analysis by Year of Establishment 13.2.2. Analysis by Company Size 13.2.3. Analysis by Location of Headquarters 13.2.4. Analysis by Location of Headquarters and Company Size 13.3. Analysis by Type of Service(s) Offered 13.3.1. Analysis by Method of Isolation 13.3.2. Analysis by Method of Purification 13.3.3. Analysis by Method of Characterization 13.3.4. Analysis by Method of Exosome Manufacturing 13.3.5. Analysis by Scale of Operation 13.3.6. Analysis by Scalability 14. DRUG FAILURE ANALYSIS 14.1. Methodology and Key Parameters 14.2. Exosome Therapeutics: List of Failed Drug Candidates 14.2.1. Analysis by Trial Start and Discontinuation Year 14.2.2. Analysis by Trial Status of Discontinuation 14.2.3. Analysis by Target Disease Indication(s) 14.2.4. Analysis by Route of Administration 14.2.5. Analysis by Type of Sponsor 14.2.6. Analysis by Reasons for Drug Failure 14.2.7. Word Cloud Analysis: Emerging Focus Area 15. MARKET SIZING AND OPPORTUNITY ANALYSIS 15.1. Forecast Methodology and Key Assumptions 15.2. Global Exosome Therapeutics Market, 2029-2040 15.2.1. Exosome Therapeutics Market for Allogeneic Therapy, 2029-2040 (USD Million) 15.2.2. Exosome Therapeutics Market for Autologous Therapy, 2029-2040 (USD Million) 15.2.3. Exosome Therapeutics Market for Degenerative Meniscal Injury, 2031-2040 (USD Million) 15.2.4. Exosome Therapeutics Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million) 15.2.5. Exosome Therapeutics Market for Fistula Perianal, 2029-2040 (USD Million) 15.2.6. Exosome Therapeutics Market for Retinitis Pigmentosa, 2029-2040 (USD Million) 15.2.7. Exosome Therapeutics Market for Dermatological Disorders, 2030-2040 (USD Million) 15.2.8. Exosome Therapeutics Market for Muscoskeletal Disorders, 2031-2040 (USD Million) 15.2.9. Exosome Therapeutics Market for Ophthalmic Disorders, 2029-2040 (USD Million) 15.2.10. Exosome Therapeutics Market for Rectal Disorders, 2029-2040 (USD Million) 15.2.11. Fistula Tract Exosome Therapeutics Market, 2029-2040 (USD Million) 15.2.12. Intra-articular Exosome Therapeutics Market, 2031-2040 (USD Million) 15.2.13. Intra-ocular Exosome Therapeutics Market, 2029-2040 (USD Million) 15.2.14. Exosome Therapeutics Market Geographical Distribution, 2029-2040 (USD Million) 15.2.15. Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million) 15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million) 15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million) 15.2.18. Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million) 15.2.19. ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million) 16. EXECUTIVE INSIGHTS 16.1. Capricor Therapeutics 16.1.1. Company Snapshot 16.1.2. Interview Transcript: Xavier Avat, Chief Business Officer 16.2. Exogenus Therapeutics 16.2.1. Company Snapshot 16.2.2. Interview Transcript: Patricia C. Freire, R&D and Innovation Manager 16.3. ILIAS Biologics 16.3.1. Company Snapshot 16.3.2. Interview Transcript: Soonho Song, Chief Business Officer 17. APPENDIX 1: TABULATED DATA 18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To view more details on this report, click on the link https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html You may also be interested in the following titles: Lab Automation Market Cannabis Testing Market You may also like to learn what our experts are sharing in Roots educational series: Antiviral Drugs Development: Are we Prepared for the Next Viral Pandemic? Exploring How Artificial Intelligence Is Transforming Digital Pathology About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #ExosomeTherapeuticsMarketTrends #ExosomeTherapeuticsMarketGrowth #exosometherapies #MSCderivedexosomes #Extracellularvesicles

Deep Learning in Drug Discovery market Size, Share, Trends by 2035 Increased capital investments and higher attrition rates have prompted the implementation of deep learning technologies to expedite drug discovery process; early-stage diagnostic capability of such technologies has also emerged as a key driver for their adoption Roots Analysis is pleased to announce the publication of its recent study, titled, “Deep Learning in Drug Discovery and Deep Learning in Diagnostics Market (2nd Edition), 2023-2035” report features an extensive study of the current market landscape and the likely future potential of the deep learning solutions market within the healthcare domain. The report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Amongst other elements, the report includes:  An executive summary of the insights captured during our research, offering a high-level view on the current state of deep learning market for drug discovery and diagnostics and its likely evolution in the mid-to-long term.  A general overview of big data revolution in the medical industry, along with information on artificial intelligence, machine learning and deep learning algorithms.  A detailed assessment of the market landscape of more than 70 companies offering deep learning technologies / services for the purpose of drug discovery, based on several relevant parameters.  A detailed assessment of the market landscape of more than 130 companies offering deep learning technologies / services for diagnostics, based on several relevant parameters.  Elaborate profiles of key players developing technologies and offering services related to deep learning, specifically for drug discovery and diagnostics.  A qualitative analysis, highlighting the five competitive forces prevalent in the deep learning domain.  An analysis of completed and ongoing clinical trials related to deep learning, based on several relevant parameters.  A detailed analysis of various investments made by players engaged in this domain, during the period 2019-2022, based on several relevant parameters.  An analysis of the start-ups / small players (established post 2015, with less than 50 employees) engaged in the deep learning market focused on drug discovery and diagnostics.  An elaborate valuation analysis of companies that are involved in the deep learning in drug discovery and diagnostics market, based on our proprietary, multi-variable dependent valuation model to estimate the current valuation / net worth of industry players.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Therapeutic Area  Oncological Disorders  Infectious Diseases  Neurological Disorders  Immunological Disorders  Endocrine Disorders  Cardiovascular Disorders  Respiratory Disorders  Ophthalmic Disorders  Musculoskeletal Disorders  Other Disorders  Key Geographical Regions  North America  Europe  Asia Pacific  Rest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companies  Mausumi Acharya (Chief Executive Officer, Advenio Technosys)  Vikas Karade (Founder, Chief Executive Officer, AlgoSurg)  Babak Rasolzadeh (Former Vice President of Product and Software Development, Arterys)  Carla Leibowitz (Head of Strategy and Marketing, Arterys)  Deekshith Marla (Founder, Chief Technology Officer, Arya.ai) and Sanjay Bhadra (Chief Business Officer, Arya.ai)  Walter de Back Former Research Scientist, Context Vision)  Kevin Choi (Chief Executive Officer, Mediwhale)  Avi Veidman (Chief Executive Officer, Nucleai), Yoav Blum (Director of AI, Nucleai) and Ken Bloom (Head of Pathology, Nucleai) Key companies / organizations covered in the report  Aegicare  Aiforia Technologies  Ardigen  Berg  Google  Huawei  Merative  Nference  Nvidia  Owkin  Phenomic AI  Pixel AI To view more details on this report, click on the link https://www.rootsanalysis.com/reports/view_document/deep-learning-in-drug-discovery-market/156.html You may also be interested in the following titles: Lipid Nanoparticles in Drug Delivery Non-Viral Transfection Reagents and Systems Market You may also like to learn what our experts are sharing in Roots educational series: Adeno-Associated Viral Vectors: Unlocking the Future Opportunities Modular Construction – Retrofitting Conventional Buildings About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #DeepLearninginDrugDiscoveryMarket #DeepLearninginDrugDiscoveryMarketSize #machinelearning #deeplearning #machinelearningalgorithms